{"id":"rhpro-uk","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5303471","moleculeType":null,"molecularWeight":"466.07"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"rhPro-UK binds to the prokineticin-2 receptor, activating downstream signaling pathways that promote angiogenesis and potentially therapeutic effects in various diseases.","oneSentence":"rhPro-UK is a recombinant human prokineticin-2 analogue that acts as a prokineticin-2 receptor agonist.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:08.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of solid tumors"}]},"trialDetails":[{"nctId":"NCT07389460","phase":"PHASE3","title":"Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2026-01-31","conditions":"Acute Ischemic Stroke","enrollment":820},{"nctId":"NCT06115070","phase":"PHASE4","title":"Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Thrombosis, Acute Ischemic Stroke (AIS)","enrollment":390},{"nctId":"NCT06841965","phase":"PHASE3","title":"Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT06749834","phase":"PHASE3","title":"Intravenous Thrombolysis and NOAC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-27","conditions":"Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT06841978","phase":"PHASE3","title":"Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":306},{"nctId":"NCT05507645","phase":"PHASE3","title":"ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-11-15","conditions":"Ischemic Stroke, Mild, Thrombosis","enrollment":1446},{"nctId":"NCT05700591","phase":"PHASE3","title":"rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2023-01-29","conditions":"Acute Ischemic Stroke","enrollment":1552},{"nctId":"NCT03108833","phase":"PHASE2","title":"A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2017-06-06","conditions":"Acute Pulmonary Embolism","enrollment":108},{"nctId":"NCT03541668","phase":"PHASE3","title":"Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2018-05-18","conditions":"Acute Ischaemic Stroke","enrollment":674},{"nctId":"NCT03578822","phase":"PHASE3","title":"Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2018-08-10","conditions":"Acute Ischaemic Stroke","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rhPro-UK","genericName":"rhPro-UK","companyName":"Tasly Biopharmaceuticals Co., Ltd.","companyId":"tasly-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"rhPro-UK is a recombinant human prokineticin-2 analogue that acts as a prokineticin-2 receptor agonist. Used for Treatment of solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}